Patients receiving enzyme replacement therapies may develop anti-drug antibodies (ADAs).
Severe gene mutations may portend greater risk of developing ADAs and poorer clinical outcomes.
Prophylactic immune tolerizing regimens have shown promise in preventing ADA development.
Better outcome measures are needed to monitor response and optimize therapeutic interventions.